YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio’s and its affiliate EG BioMed Co., Ltd.’s (“EG BioMed”) participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026. The companies showcased their advancements and offerings across: ophthalmic regenerative medicine, DNA-based cancer detection, and U.S. market entry services for life science partners.

Advancements in Ophthalmology: Commercial and Clinical Progress YD Bio highlighted its dual-track approach to eye care, featuring both market-ready products and innovative clinical developments: * Exovisse(™) Eye Care: Developed in partnership with 3D Global Biotech Inc., this product line features preservative-free artificial tears and contact lenses. The over-the-counter artificial tears meet FDA standards and are designed to support the eye’s natural healing process, offering long-lasting relief suitable for daily use. The product is currently authorized for nationwide sale in the U.S. * Limbal Stem Cell (LSC) Exosome Therapy: YD Bio is advancing a regenerative therapy utilizing exosomes—natural, nanoscale particles that facilitate cellular repair—to treat ocular surface diseases. This approach is intended to reduce the immune rejection risks often associated with traditional cell therapies while offering a highly standardized manufacturing process. The LSC materials are registered in the FDA Drug Master File, with an Investigational New Drug (IND) application for dry eye disease expected in 2026 and initial human trials slated for 2027. This therapy is currently in development and is not yet an FDA approved product. Expanding Footprint in Oncology Diagnostics EG BioMed showcased its integrated EG Telehealth Platform, which streamlines the patient’s journey from remote physician consultations to lab analysis and follow-up care.